↓ Skip to main content

Role of Nutraceuticals in Hypolipidemic Therapy

Overview of attention for article published in Frontiers in Cardiovascular Medicine, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
10 X users
facebook
1 Facebook page

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
79 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Role of Nutraceuticals in Hypolipidemic Therapy
Published in
Frontiers in Cardiovascular Medicine, May 2015
DOI 10.3389/fcvm.2015.00022
Pubmed ID
Authors

Carlo M. Barbagallo, Angelo Baldassare Cefalù, Davide Noto, Maurizio R. Averna

Abstract

Nutraceuticals are food components or active ingredients present in foods and used in therapy. This article analyzes the characteristics of the molecules with a lipid-lowering effect. The different nutraceuticals may have different mechanisms of action: inhibition of cholesterol synthesis primarily through action on the enzyme HMG-CoA reductase (policosanol, polyphenols, garlic and, above all, red yeast rice), increase in LDL receptor activity (berberine), reduction of intestinal cholesterol absorption (garlic, plant sterols, probiotics), and also the ability to interfere with bile metabolism (probiotics, guggul). Based on the different mechanisms of action, some nutraceuticals are then able to enhance the action of statins. Nutraceuticals are often used without relevant evidence: mechanisms of action are not clearly confirmed; most of clinical data are derived from small, uncontrolled studies, and finally, except for fermented red rice, there are no clinical trials which may document the relationship between these interventions and the reduction of clinical events. Therefore, among all nutraceuticals, it is necessary to extrapolate those having a really documentable efficacy. However, these kinds of treatments are usually well-tolerated by patients. Overall, subjects with a middle or low cardiovascular risk are the best indication of nutraceuticals, but they may also be useful for patients experiencing side effects during classical therapies. Finally, in consideration of the additive effect of some nutraceuticals, a combination therapy with classical drugs may improve the achievement of clinical targets. Thus, nutraceuticals may be a helpful alternative in hypolipidemic treatment and, if properly used, might represent a valid strategy of cardiovascular prevention.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 1%
Unknown 78 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 15 19%
Student > Bachelor 13 16%
Researcher 12 15%
Student > Ph. D. Student 11 14%
Student > Postgraduate 4 5%
Other 10 13%
Unknown 14 18%
Readers by discipline Count As %
Medicine and Dentistry 18 23%
Agricultural and Biological Sciences 11 14%
Biochemistry, Genetics and Molecular Biology 10 13%
Pharmacology, Toxicology and Pharmaceutical Science 8 10%
Immunology and Microbiology 2 3%
Other 12 15%
Unknown 18 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 May 2021.
All research outputs
#5,657,080
of 22,835,198 outputs
Outputs from Frontiers in Cardiovascular Medicine
#849
of 6,719 outputs
Outputs of similar age
#66,180
of 264,317 outputs
Outputs of similar age from Frontiers in Cardiovascular Medicine
#2
of 10 outputs
Altmetric has tracked 22,835,198 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,719 research outputs from this source. They receive a mean Attention Score of 4.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,317 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.